EGFR-Based Targeted Therapy for Colorectal Cancer-Promises and Challenges.

Area of Science:

• Oncology
• Nanomedicine
• Drug Delivery

Background:

• Colorectal carcinoma (CRC) is a leading cause of cancer mortality worldwide, with a significant percentage diagnosed at advanced metastatic stages.
• Metastatic CRC presents challenges for surgical intervention and contributes to high tumor-related mortality.
• Current diagnostic and therapeutic strategies for CRC require enhancement, particularly for advanced disease.

Purpose of the Study:

• To review nanotherapy approaches for colorectal carcinoma treatment.
• To examine the efficacy of drug carriers conjugated with cetuximab for targeting epidermal growth factor receptor (EGFR) in CRC.
• To highlight the potential of active targeting strategies in improving chemotherapeutic drug delivery.

Main Methods:

• Review of literature on targeted nanotherapy in colorectal cancer.
• Analysis of drug delivery systems utilizing antibodies targeting overexpressed cell surface receptors.
• Focus on EGFR as a key target due to its high prevalence in CRC.

Main Results:

• Active targeting enhances drug delivery effectiveness and quantity to tumor sites.
• EGFR is a crucial target in CRC, overexpressed in 25-82% of cases.
• Cetuximab and panitumumab are EGFR monoclonal antibodies with therapeutic potential for CRC.

Conclusions:

• Cetuximab-conjugated nanocarriers represent a promising strategy for colorectal cancer treatment.
• Targeting EGFR with nanotherapy offers a pathway for improved tumor selection and drug delivery.
• Further investigation into the efficacy of these targeted nanotherapies is warranted for advanced CRC.